AllianceBernstein’s LENZ Therapeutics LENZ Stock Holding History

AllianceBernstein’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Buy	26,386 +13,000	+97%	+$105K	﹤0.01%	3083
2026 Q1	$214K	Hold	13,386	–	–	﹤0.01%	3024
2025 Q4	$214K	Sell	13,386 -1,720	-11%	-$50.1K	﹤0.01%	3043
2025 Q3	$704K	Hold	15,106	–	–	﹤0.01%	2508
2025 Q2	$443K	Buy	15,106 +5,800	+62%	+$158K	﹤0.01%	2715
2025 Q1	$239K	Buy	9,306 +1,720	+23%	+$42.4K	﹤0.01%	2865
2024 Q4	$219K	Sell	7,586 -1,760	-19%	-$53.6K	﹤0.01%	3006
2024 Q3	$222K	Buy	+9,346	New	+$207K	﹤0.01%	3009

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

AllianceBernstein's LENZ Position: Q2 2026 in Review

AllianceBernstein increased its LENZ Therapeutics (LENZ) stake by 97% in Q2 2026, buying an estimated $105K and bringing the position to 26,386 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #3083.

AllianceBernstein first reported a position in LENZ in Q3 2024 and has held it in 8 quarters since. The position peaked at $704K in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

AllianceBernstein held 26,386 shares of LENZ Therapeutics worth $241K as of Q2 2026.
AllianceBernstein bought 13,000 LENZ Therapeutics shares in Q2 2026, an estimated $105K.
LENZ Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3083 holding.
AllianceBernstein first reported a position in LENZ Therapeutics in Q3 2024 and has held it in 8 quarters since.
AllianceBernstein's LENZ Therapeutics position peaked at $704K in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.